Can stem cell therapy “cure” ED?

Data from eight patients in a small clinical trial have suggested that stem-cell therapy may be able to restore erectile function in men treated for prostate cancer by radical prostatectomy. … READ MORE …

Escalated radiation dose doesn’t improve 8-year overall survival in intermediate-risk men (but does it matter?)

Last week, we saw that escalated dose did not improve 10-year overall survival in high-risk men (see this link). The latest published findings of the randomized clinical trial (RTOG 0126) prove that 8-year overall survival was not improved in intermediate-risk men who received a higher radiation dose. … READ MORE …

PSA “bounces” after first-line radiation therapy

Perhaps the single most annoying “side effect” of radiation therapy for prostate cancer is not a side effect at all; it’s the periodic fluctuations in PSA, called “bounces,” that can occur for years after therapy. … READ MORE …

Erectile function after SBRT

Erectile function after radiation therapy is of great interest to many men trying to decide between surgery and radiation, and to decide among the several radiation treatment options. … READ MORE …

New study: adjuvant radiation therapy saves lives vs. salvage

A major new study adds to several other studies that show that, for men with adverse pathology, adjuvant radiation (ART) within 3 to 6 months of prostatectomy saves more lives compared to waiting until the PSA rises into the range of 0.1 to 0.5 ng/ml — salvage radiation (SRT). … READ MORE …

Hyperthermia and radiation therapy

Many years ago, it was discovered that a moderate increase in tissue temperature can markedly improve the cancer cell killing power of ionizing radiation. … READ MORE …

When can ADT be safely avoided with salvage radiation therapy?

Two randomized clinical trials (GETUG-AFU-16 and RTOG 9601) proved that adding at least some ADT to salvage radiation (SRT) improved outcomes. “Some ADT” was 6 months of goserelin acetate in the GETUG-AFU-16 trial, and 2 years of bicalutamide in the RTOG 9601 trial. … READ MORE …